Biotechnology US drugmaker Sarepta Therapeutics last revealed that it has received a negative trend vote following its European Medicines Agency/Committee for Medicinal Products for Human Use (CHMP) oral explanation for its key Duchenne muscular dystrophy (DMD) drug Exondys 51 (eteplirsen) and it will request a re-examination and Scientific Advisory Group to be convened. 7 May 2018